Endobronchial Gene Therapy

Kruklitis, and Robert J.; Sterman, Daniel H.

doi:10.1002/9780470755969.ch13

Search citation statements

Order By: Relevance

Paper Sections

Select...

Gene Therapies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past few decades, a number of studies evaluating endobronchial gene therapy have been performed [35][36][37][38][39][40][41][42][43][44], and have been reviewed elsewhere [88][89][90][91]. Many trials involved injection of adenoviral vector with the wild-type p53 tumour suppressor gene injected via bronchoscopic or percutaneous injection into tumours with absent or mutated p53.…”

Section: Gene Therapiesmentioning

confidence: 99%

Bronchoscopic intratumoural therapies for non-small cell lung cancer

DeMaio¹,

Sterman²

2020

Eur Respir Rev

View full text Add to dashboard Cite

The past decade has brought remarkable improvements in the treatment of non-small cell lung cancer (NSCLC) with novel therapies, such as immune checkpoint inhibitors, although response rates remain suboptimal. Direct intratumoural injection of therapeutic agents via bronchoscopic approaches poses the unique ability to directly target the tumour microenvironment and offers several theoretical advantages over systemic delivery including decreased toxicity. Increases in understanding of the tumour microenvironment and cancer immunology have identified many potential options for intratumoural therapy, especially combination immunotherapies. Herein, we review advances in the development of novel bronchoscopic treatments for NSCLC over the past decade with a focus on the potential of intratumoural immunotherapy alone or in combination with systemic treatments.

show abstract